Clinical trials
Locally Advanced Cervical Cancer clinical trials
Below are recruiting locally advanced cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 406 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07053072RecruitingPhase 1
PD-1 mRNA vaccine for advanced liver cancer
This trial tests a new mRNA vaccine for people with advanced liver cancer that has returned or spread after other treatments. The vaccine aims to help your immune system fight the cancer more effectively.
Chengdu, SichuanAges 18–70 - NCT07096258Recruiting
Blood test to guide first treatment for advanced lung cancer
This trial is for people with advanced non-small cell lung cancer (NSCLC) who have not yet started treatment. It studies a simple blood test that checks for genetic changes in the cancer, to help doctors choose the most effective first treatment.
Nancy, LorraineAges 18 years+ - NCT03526835RecruitingPhase 1/Phase 2
Study of MCLA-158 for advanced solid tumors
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
La Jolla, CaliforniaAges 18 years+ - NCT06793813RecruitingPhase 2
Study of cadonilimab for advanced lung cancer
This trial tests a new drug called cadonilimab for people with advanced non-squamous non-small cell lung cancer that has gotten worse after treatment with immunotherapy and chemotherapy. The goal is to see if it helps control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06915025RecruitingPhase 3
Study of a new drug for advanced ovarian cancer
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
Orlando, FloridaAges 18 years+ - NCT05467748RecruitingPhase 1/Phase 2
Study drug combo for advanced lung cancer after PD-1 treatment
This Phase 1/2 trial tests a combination of an EZH2 inhibitor (tulmimetostat) with a PD-1 blocker (pembrolizumab) for advanced non-small cell lung cancer that has stopped responding to prior PD-1 treatment. It may help shrink or control cancer and is mainly aimed at people who have limited treatment options left.
Long Beach, CaliforniaAges 18 years+ - NCT06907615RecruitingPhase 2
Study of HLX43 for advanced non-small cell lung cancer
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT03740256RecruitingPhase 1
HER2-targeted oncolytic virus plus custom immune cells for solid cancers
This Phase 1 study tests a treatment plan that combines a virus designed to attack cancer with your own custom immune cells that target HER2. It aims to shrink advanced HER2-positive solid tumors (and make future options safer/more effective).
Houston, TexasAges 18 years+ - NCT06362980RecruitingPhase 1
BPI-1178 plus osimertinib for EGFR-mutated lung cancer
This trial tests a new drug (BPI-1178) combined with osimertinib for advanced lung cancer with EGFR mutations. It’s for people whose cancer has progressed after prior treatment with a third-generation EGFR targeted therapy.
BeijingAges 18 years+ - NCT07349160RecruitingEarly Phase 1
Metabolically armed TIL therapy for advanced solid tumors
This trial tests a new cell therapy called Meta10-TIL, where immune cells from your tumor are modified and given back to you to help fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments.
BeijingAges 19–70 - NCT06788938RecruitingPhase 2
Tarlatamab for advanced DLL3-positive tumors
This trial tests a drug called tarlatamab for people with advanced cancers that have a specific protein called DLL3. It aims to see if this treatment can help when other treatments have stopped working.
Davis, CaliforniaAges 18 years+ - NCT03736863RecruitingPhase 2
Testing combinations of medicines for advanced throat cancer
This trial tests a combination of medicines to treat advanced esophageal squamous cell carcinoma (throat/esophagus cancer) that cannot be removed by surgery and has spread or come back. It is for people whose first treatment (chemotherapy or immunotherapy) did not work well or was not tolerated.
Zhengzhou, HenanAges 18–75 - NCT05830500RecruitingPhase 4
Anlotinib for advanced medullary thyroid cancer
This trial studies anlotinib in people with advanced or metastatic medullary thyroid cancer that has been getting worse. It aims to see how well the treatment controls the cancer and how safe it is for patients who can’t have curative surgery.
Hefei, AnhuiAges 18–75 - NCT06742411RecruitingPhase 1/Phase 2
Chemo plus immunotherapy and hyperbaric oxygen for advanced stomach cancer
This trial tests a combination of chemotherapy (XELOX), an immunotherapy drug (Sintilimab), and hyperbaric oxygen therapy for people with advanced or metastatic stomach or gastroesophageal junction cancer. The goal is to see if this triple therapy helps shrink or control the cancer better than current options.
Chengdu, SichuanAges 18–75 - NCT06753747RecruitingPhase 1/Phase 2
Afatinib and palbociclib for advanced esophageal cancer
This trial tests a combination of two targeted drugs (afatinib and palbociclib) for people with advanced esophageal squamous cell carcinoma that has grown after previous treatment. It is designed for those whose cancer cells have too much of a protein called EGFR.
Chengdu, SichuanAges 18–75 - NCT07217171RecruitingPhase 1
Study of EVOLVE104 for advanced bladder and squamous cell cancers
This trial tests an experimental drug called EVOLVE104 for people with advanced bladder cancer or certain types of squamous cell cancers. It aims to see if the drug is safe and if it can help shrink tumors.
Duarte, CaliforniaAges 18 years+ - NCT06502743RecruitingPhase 2
Study of chemotherapy and pembrolizumab with or without nesuparib for endometrial cancer
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
Kyeonggi-doAges 19 years+ - NCT06451497RecruitingPhase 1
Testing ZM008 alone and with toripalimab for advanced cancers
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT07704177RecruitingPhase 2
A study of trastuzumab rezetecan plus two other drugs for advanced bile duct cancer
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has HER2 protein on its cells. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT05451784RecruitingPhase 1/Phase 2
PD-1 TIL therapy for advanced triple-negative breast cancer
This study tests an immune-cell treatment made from your tumor tissue. It aims to help people with advanced or metastatic triple-negative breast cancer by collecting PD-1–positive immune cells and giving them back after treatment.
BarcelonaAges 18 years+ - NCT06730347RecruitingPhase 2
Study of lorigerlimab for advanced ovarian and other cancers
This trial tests a new drug, lorigerlimab, for people with certain types of ovarian cancer or related cancers that have come back or not responded to treatment. The goal is to see if the drug can help shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06747585RecruitingPhase 1/Phase 2
ALE.P02 for advanced squamous cell cancers with CLDN1
This trial tests a new drug called ALE.P02 for people with advanced squamous cell cancers (like lung, head and neck, esophagus, or skin cancer) that have a certain protein called CLDN1. The drug is given alone and aims to shrink or stop the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT07670273RecruitingPhase 2
Drug combo for advanced HER2 bile duct cancer
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) as a first treatment for people with advanced HER2-positive or HER2-low bile duct or gallbladder cancer. The goal is to see if this combination helps shrink or control the cancer.
BeijingAges 18–75 - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+
Hear when a new Locally Advanced Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced cervical cancer?
- Yes. Clin2 currently lists 406 recruiting locally advanced cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Rectal Cancer
- Locally Advanced Breast Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Locally Advanced Pancreatic Cancer
- Locally Advanced Gastric Cancer
- Locally Advanced Cervical Carcinoma
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.